MiR-145–5p reduced ANG II-induced ACE2 shedding and the inflammatory response in alveolar epithelial cells by targeting ADAM17 and inhibiting the AT1R/ADAM17 pathway

Xu'an Wang,Jun Ma,Duomao Lin,Yang Bai,Dongni Zhang,Xiaotong Jia,Junwei Gao
DOI: https://doi.org/10.1016/j.ejphar.2024.176392
IF: 5.195
2024-02-17
European Journal of Pharmacology
Abstract:The excessive elevation of angiotensin II (ANG II) is closely associated with the occurrence and development of aortic dissection (AD)-related acute lung injury (ALI), through its binding to angiotensin II receptor type I (AT1R). MiR-145–5p is a noncoding RNA that can be involved in a variety of cellular physiopathological processes. Transfection with miR-145–5p was found to downregulated the expression of A disintegrin and metalloprotease 17 (ADAM17) and reduced the levels of angiotensin-converting enzyme 2 (ACE2) in lung tissue, while concurrently increasing plasma ACE2 levels in the AD combined with ALI mice. ADAM17 was proved to be a target of miR-145–5p. Transfection with miR-145–5p decreased the shedding of ACE2 and alleviated the inflammatory response induced by ANG II through targeting ADAM17 and inhibiting the AT1R/ADAM17 pathway in A549 cells. In conclusion, our present study demonstrates the role and mechanism of miR-145–5p in alleviating ANG II-induced acute lung injury, providing a new insight into miRNA therapy for reducing lung injury in patients with aortic dissection.
pharmacology & pharmacy
What problem does this paper attempt to address?